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Rheumatoid arthritis (RA) is a polygenic disease associated with accelerated atherosclerosis and increased cardiovascular (CV)
mortality. JAK/STAT signalling pathway is involved in autoimmune diseases and in the atherosclerotic process. JAK3 is a highly
promising target for immunomodulatory drugs and polymorphisms in JAK3 gene have been associated with CV events in incident
dialysis patients. Therefore, the aim of this study was to assess the potential role of JAK3 polymorphisms in the development of CV
disease in patients with RA. 2136 Spanish RApatients were genotyped for the rs3212780 and rs3212752 JAK3 gene polymorphisms by
TaqMan assays. Subclinical atherosclerosis was evaluated in 539 of these patients by carotid ultrasonography (US). No statistically
significant differences were found when each polymorphism was assessed according to carotid intima-media thickness values
and presence/absence of carotid plaques in RA, after adjusting the results for potential confounders. Moreover, no significant
differences were obtained when RA patients were stratified according to the presence/absence of CV events after adjusting for
potential confounders. In conclusion, our results do not confirm association between JAK3 polymorphisms and CV disease in RA.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory rheu-
matic disease associated with an increased risk for car-
diovascular (CV) events and CV-related deaths compared
with the general population [1]. Evidence indicates that RA
is an independent risk factor for premature heart disease
[2]. This process can be partly explained by traditional
CV risk factors [3], magnitude, and severity of a chronic
inflammatory response [4], and genetic factors located inside
[4] and outside the Human Leukocyte Antigen (HLA) region
[5–8].
Janus kinases (JAKs) play a pivotal role in cytokine recep-
tor signalling since they phosphorylate and activate signal
transducer and activator of transcription (STAT) proteins.
Several of these JAK-controlled cytokine receptor pathways
are intimately involved in the initiation andprogression of RA
disease pathogenesis, autoimmune type-1 diabetes, systemic
lupus erythematosus, and other autoimmune diseases [9–11].
The JAK/STAT pathway is a widely expressed intracellular
signal transduction pathway, fundamentally important for
T lymphocyte differentiation and function [12, 13]. This is
of particular relevance since CD4+ T helper type 1 (TH1)
cells are believed to promote atherosclerotic lesions and acute
coronary syndromes, while T helper type 2 (TH2) cells likely
serve an inhibitory or modulatory role [14, 15]. Furthermore,
this signalling pathway controls important inflammatory
processes in vascular cells, and its activation is involved in
atherosclerosis and hypertension [16, 17].
JAK3 is the only Jak family member that associates with
just one cytokine receptor, the common 𝛾 (𝛾c) chain, which
is exclusively used by the receptors for IL-2, IL-4, IL-7, IL-
9, IL-15, and IL-21 [11]. Although JAK1, JAK2, and Tyk2
are expressed ubiquitously, JAK3 expression is restricted to
hematopoietic lineage cells [18]. The genes encoding the JAK
family members are located on three separate chromosomes.
The JAK1 and JAK2 genes are located on human chromo-
somes 1p31.3 and 9p24. In contrast, the gene coding for JAK3
is located on human chromosome 19p13.1 [18].
Different genetic variants located in the JAK3 gene have
been associated with some inflammatory disorders including
the development of CV events in incident dialysis patients
[19]. Interestingly, tofacitinib, a molecule that inhibits JAK3
and JAK1 and to a lesser extent JAK2, has shown robust and
sustained efficacy in patients with RA [20].
Taking into account all these considerations, the main
purpose of this study was to determine, for the first time
whether JAK3 gene variants inRApatients are associatedwith
the presence of subclinical atherosclerosis and CV events.
2. Patients and Methods
2.1. Patients and Study Protocol. Aset of 2136 Spanish patients
with RA were included in the present study. Blood samples
were obtained from patients recruited from Hospital Lucus
Augusti (Lugo), Hospital Marque´s de Valdecilla (Santander),
Hospital de Bellvitge (Barcelona), Hospital Cl´ınico San Car-
los, Hospital La Paz, Hospital La Princesa, Hospital Gregorio
Table 1: Demographic characteristics of the RA patients.
Clinical features % (𝑛/𝑁)
Patients 2136
Main characteristics
Age at the time of disease onset
(years, mean ± SD) 50.8 ± 14.8
Follow-up (years, mean ± SD) 11.6 ± 8.3
Percentage of women 75.2
Rheumatoid factor positive∗ 69.1 (1430/2071)
Anti-CCP antibodies positive 59.1 (1063/1799)
Shared epitope positive 62.6 (762/1217)
Erosions 55 (902/1640)
Extra-articular manifestations∗∗ 31.1 (511/1640)
Cardiovascular risk factors
Hypertension 38.5 (810/2102)
Diabetes mellitus 12.4 (261/2102)
Dyslipidemia 36.0 (757/2102)
Obesity 18.1 (381/2102)
Smoking habit 24.5 (517/2102)
Patients with cardiovascular events 17.9 (384/2136)
Ischemic heart disease 8.4 (180/2136)
Heart failure 5.9 (126/2136)
Cerebrovascular accident 5.2 (112/2136)
Peripheral arteriopathy 2.4 (52/2136)
RA: rheumatoid arthritis; 𝑛: number of patients; SD: standard deviation;
Anti-CCP antibodies: anti-cyclic citrullinated peptide antibodies.
∗At least two determinations were required for analysis of this result.
∗∗Extra-articularmanifestations of the disease (if RA patients experienced at
least one of the following manifestations: nodular disease, Felty’s syndrome,
pulmonary fibrosis, rheumatoid vasculitis, or secondary Sjo¨gren’s syndrome)
[4].
Maran˜o´n, and Hospital 12 de Octubre (Madrid). A subject’s
written consent was obtained in all the cases. The Ethics
Committees of the corresponding hospitals approved the pur-
pose of the work. All the patients fulfilled the 1987 American
College of Rheumatology (ACR) and the 2010 classification
criteria for RA [21, 22]. Patients were assessed for rs3212780
and rs3212752 JAK3 gene variants. In addition, carotid
intima-media thickness (cIMT) and presence/absence of
carotid plaques were determined by carotid ultrasonography
(US) in 539 of these patients.
Information on the main demographic data, clinical
characteristics, CV risk factors, and CV events of patients
enrolled in the study is shown in Table 1. Additionally, the
18% of these patients had experienced CV events, 75.2% were
women and themean age at the time of disease onset was 50.8
years.Definitions ofCVevents and traditional CV risk factors
were established as previously described [4].
2.2. Genotyping. DNA from patients was obtained from
peripheral blood using standard methods.
BioMed Research International 3
Table 2: Differences in genotype and allele frequencies of JAK3 polymorphisms between RA patients with or without cardiovascular (CV)
events.
SNP 1/2 Subgroup Genotype,𝑁 (%) Allele test
1/1 1/2 2/2 MAF 𝑃∗ OR [95% CI]∗
rs3212780 G/A Without CV events 909 (52.51) 688 (39.75) 134 (7.74) 0.28
With CV events 191 (50.26) 160 (42.11) 29 (7.63) 0.29 0.51 0.93 [0.75–1.06]
rs3212752 T/C Without CV events 1547 (88.30) 203 (11.59) 2 (0.11) 0.06
With CV events 349 (90.88) 34 (8.85) 1 (0.26) 0.05 0.35 0.81 [0.52–1.26]
RA: rheumatoid arthritis. CV: cardiovascular. SNP: single nucleotide polymorphisms. MAF: minor allele frequency. OR: odds ratio. CI: confidence interval.
∗Adjusted for sex, age at the time of ultrasonography study, follow-up time, and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia,
obesity, and smoking habit) by logistic regression.
The rs3212780 and rs3212752 JAK3 polymorphisms were
genotyped with TaqMan predesigned single-nucleotide poly-
morphism genotyping assays in a 7900 HT Real-Time
polymerase chain reaction (PCR) system, according to the
conditions recommended by the manufacturer (Applied
Biosystems, Foster City, CA, USA). Negative controls and
duplicate samples were included to check the accuracy of
genotyping.
2.3. Carotid US Examination. Measurement of the cIMT and
presence/absence of carotid plaques were performed in 539
patients from Lugo and Santander by carotid US. Patients
from Santander were assessed using a commercially available
scanner, Mylab 70, Esaote (Genoa, Italy) equipped with 7–
12MHz linear transducer and the automated software guided
technique radiofrequency—Quality Intima Media Thickness
in real-time (QIMT, Esaote, Maastricht, Holland)—was used
[23, 24]. Patients from Lugo were assessed using high-
resolution B-mode ultrasound, Hewlett Packard SONOS
5500, with a 10MHz linear transducer as previously reported
[25]. cIMT was measured at the far wall of the right and left
common carotid arteries, 10mm from the carotid bifurcation,
over the proximal 15mm-long segment. cIMT was deter-
mined as the average of threemeasurements in each common
carotid artery. The final cIMT was the largest average cIMT
(left or right).Theplaque criteria in the accessible extracranial
carotid tree (common carotid artery, bulb, and internal
carotid artery) were focal protrusion in the lumen at least
cIMT >1.5mm, protrusion at least 50% greater than the
surrounding cIMT, or arterial lumen encroaching >0.5mm,
according to Mannheim consensus criteria [26]. The carotid
plaques were counted in each territory and defined as no
plaque, unilateral plaque, or bilateral plaques [23, 24, 27].
Agreement between the two US methods in patients with
RA was previously reported [27]. Two experts with high
experience and close collaboration in the assessment of
subclinical atherosclerosis in RA from Santander (AC) and
Lugo (CGJ) performed the studies.
2.4. Statistical Analysis. All genotype data were checked for
deviation from Hardy-Weinberg equilibrium (HWE) using
http://ihg.gsf.de/cgi-bin/hw/hwa1.pl.
cIMT values are displayed as mean and standard devi-
ation (SD). The association between genotypes and alleles
of each polymorphism and cIMT values was tested using
unpaired 𝑡-test to compare between 2 groups and one-way
analysis of variance (ANOVA) to compare among more than
two groups. Comparisons of means was adjusted for sex, age
at the time of US study, follow-up time and traditional CV
risk factors (hypertension, diabetes mellitus, dyslipidemia,
obesity, and smoking habit) as potential confounders using
analysis of covariance (ANCOVA).
Differences in the genotypic and allelic frequencies of
each polymorphism according to the presence/absence of
carotid plaques andCV events were calculated by𝜒2 or Fisher
tests when necessary (expected values below 5). Strength
of associations were estimated using odds ratios (OR) and
95% confidence intervals (CI). Results were adjusted for sex,
age at the time of US study, and traditional CV risk factors
(hypertension, diabetes mellitus, dyslipidemia, obesity, and
smoking habit) by logistic regression.
Statistical significance was defined as 𝑃 < 0.05. All
analyses were performed with STATA statistical software
12/SE (Stata Corp., College Station, TX, USA).
3. Results
The JAK3 rs3212780 and rs3212752 genotype distributionwere
in Hardy-Weinberg equilibrium.
As shown in Table 2, no differences were observed when
genotype and allele frequencies from patients with or without
CV events were compared for rs3212780 and rs3212752 gene
variants. Results from an adjusted logistic regression model
did not show statistically significant association between
rs3212780 or rs3212752 gene polymorphisms and the risk of
CV events.
As shown inTable 3, no statistically significant differences
were foundwhen each polymorphismwas assessed according
to the evaluation of the cIMT in RA patients, after adjusting
the results for sex, age at the time of US study and traditional
CV risk factors (hypertension, diabetes mellitus, dyslipi-
demia, obesity, and smoking habit) as potential confounders.
Similarly, no statistically significant differences were detected
when each polymorphism was evaluated according to the
presence/absence of carotid plaques in RA, after adjusting
the results for potential cofounder factors specified above
(Table 3).
Taking into account the implication of JAK3 in inflam-
matory diseases and the relevant role of C-reactive protein
(CRP) in inflammation, we assessed the potential association
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Table 3: Association between JAK3 polymorphisms and carotid intima-media thickness (cIMT) and presence/absence of carotid plaques in
RA patients.
𝐽𝐴𝐾3 Genotypes/alleles cIMT mm Presence versus absence of carotid plaques
Mean ± SD 𝑃∗ OR [95% CI]∗∗ 𝑃∗∗
rs3212780
GG (𝑛 = 285) 0.73 ± 0.17 Ref.
GA (𝑛 = 210) 0.73 ± 0.17 1.13 [0.79–1.61] 0.51
AA (𝑛 = 44) 0.77 ± 0.22 0.38 1.54 [0.80–2.96] 0.20
G (𝑛 = 780) 0.73 ± 0.17
A (𝑛 = 298) 0.74 ± 0.19 0.56 1.19 [0.91–1.56] 0.50
rs3212752
TT (𝑛 = 477) 0.73 ± 0.18 Ref.
TC (𝑛 = 60) 0.74 ± 0.17 0.17 0.61 [0.35–1.05] 0.15
CC (𝑛 = 0) — — — —
T (𝑛 = 1014) 0.74 ± 0.17
C (𝑛 = 60) 0.74 ± 0.17 0.17 0.62 [0.37–1.06] 0.15
RA: rheumatoid arthritis. cIMT: Carotid intima-media thickness. SD: standard deviation. OR: Odds Ratio. CI: confidence interval.
∗Adjusted for sex, age at the time of ultrasonography study, follow-up time, and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia,
obesity, and smoking habit) using analysis of covariance (ANCOVA).
∗∗Adjusted for sex, age at the time of ultrasonography study, follow-up time, and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia,
obesity, and smoking habit) by logistic regression.
Table 4: Association between JAK3 polymorphisms and CRP levels
in RA patients.
𝐽𝐴𝐾3 Genotypes/alleles CRP mg/L 𝑃∗
Mean ± SD
rs3212780
GG (𝑛 = 311) 15.2 ± 25.9 0.58
GA (𝑛 = 234) 13.5 ± 20.1
AA (𝑛 = 58) 17.8 ± 30.6
G (𝑛 = 856) 14.9 ± 24.4 0.99
A (𝑛 = 350) 14.9 ± 24.1
rs3212752
TT (𝑛 = 534) 14.7 ± 24.4 0.97
TC (𝑛 = 72) 14.5 ± 23.7
CC (𝑛 = 2) 6.6 ± 7.2
T (𝑛 = 1140) 14.7 ± 24.3 0.95
C (𝑛 = 76) 14.1 ± 23.2
Haplotypes
GT (820) 14.7 ± 24.3 0.92
AT (304) 15.4 ± 24.9
AC (41) 13.1 ± 17.7
GC (31) 16.7 ± 30.1
CRP: C-Reactive Protein; RA: rheumatoid arthritis; SD: standard deviation.
∗Adjusted for potential confounder factors.
between JAK3 polymorphisms and CRP levels in a repre-
sentative subgroup of patients in whom CRP information
was available. As shown in Table 4, we did not disclose a
relationship between CRP levels neither with JAK3 genotypes
and alleles nor haplotypes.
Finally, we also evaluated whether there were differences
in cIMT values and presence/absence of carotid plaques
between patients positive and negative for rheumatoid factor
(RF) and/or anti-cyclic citrullinated peptide antibodies (anti-
CCP) in relation to JAK3 gene polymorphisms. We per-
formed this study in a subgroup of patients in whom carotid
ultrasound and clinical and laboratory data were available. In
this regard, no significant results were obtained in any of the
analyses (Tables 5, 6, 7, 8, 9, and 10).
4. Discussion
CV disease is the main cause of death in patients with RA
[4]. Therefore, a better understanding of the mechanisms
involved in this disorder has become of main importance.
During the last years, several genetic markers have been
involved in CV disease susceptibility and progression in
patients with RA [4–8].
JAK3 is a potential target for immunomodulatory drugs
since it is involved in key inflammatory pathways in both
autoimmune and CV diseases. In accordance, several phar-
maceutical companies have reported JAK inhibitors in var-
ious stages of clinical development [28], and some clinical
trials are ongoing to monitor the efficacy and safety of JAK3
inhibitor tofacitinib [29, 30].
JAK3 polymorphisms have been associated with CV
events in incident dialysis patients [19]. Because of that, in this
studywe analyzed twowell-knownpolymorphisms rs3212780
and rs3212752 located in the JAK3 gene. To the best of our
knowledge, this is the first study performed to evaluate the
potential influence of JAK3 polymorphisms in the risk of
CV disease and subclinical atherosclerosis in an RA cohort.
However, we did not observe any statistically significant
differences when each polymorphismwas assessed according
to cIMT values and presence or absence of carotid plaques
in RA. Besides an absence of association with subclinical
atherosclerosis, we did not observe significant differences
when RA patients were stratified according to the presence or
absence of CV events.The discrepancy observed between our
results and the ones obtained in incident dialysis patients [19]
may be explained by the fact that both populations displayed
very different characteristics. In this regard, and in contrast
to the population described by Sperati et al. [19], the vast
BioMed Research International 5
Table 5: Association between cIMT values and JAK3 polymor-
phisms in RA patients stratified according to anti-CCP status.
Subgroup 𝐽𝐴𝐾3 Genotypes/alleles cIMT (mm) 𝑃∗
Mean ± SD
Anti-CCP
positive
rs3212780
GG (𝑛 = 137) 0.73 ± 0.17 0.55
GA (𝑛 = 97) 0.73 ± 0.18
AA (𝑛 = 21) 0.77 ± 0.23
G (𝑛 = 371) 0.73 ± 0.17 0.50
A (𝑛 = 139) 0.74 ± 0.19
rs3212752
TT (𝑛 = 224) 0.73 ± 0.17 0.25
TC (𝑛 = 31) 0.77 ± 0.18
CC (𝑛 = 0) —
T (𝑛 = 479) 0.73 ± 0.18 0.27
C (𝑛 = 31) 0.77 ± 0.18
Haplotypes
GT (𝑛 = 355) 0.73 ± 0.17 0.53
AT (𝑛 = 124) 0.74 ± 0.19
AC (𝑛 = 15) 0.73 ± 0.21
GC (𝑛 = 16) 0.77 ± 0.17
Anti-CCP
negative
rs3212780
GG (𝑛 = 127) 0.71 ± 0.16 0.78
GA (𝑛 = 102) 0.73 ± 0.17
AA (𝑛 = 22) 0.77 ± 0.19
G (𝑛 = 356) 0.72 ± 0.16 0.53
A (𝑛 = 146) 0.74 ± 0.17
rs3212752
TT (𝑛 = 225) 0.72 ± 0.17 0.53
TC (𝑛 = 24) 0.73 ± 0.15
CC (𝑛 = 0) —
T (𝑛 = 474) 0.72 ± 0.17 0.54
C (𝑛 = 24) 0.73 ± 0.15
Haplotypes
GT (𝑛 = 342) 0.72 ± 0.16 0.79
AT (𝑛 = 132) 0.75 ± 0.18
AC (𝑛 = 14) 0.73 ± 0.17
GC (𝑛 = 10) 0.73 ± 0.11
cIMT: carotid intima-media thickness; anti-CCP: anti-cyclic citrullinated
peptide; RA: rheumatoid arthritis; SD: standard deviation.
∗Adjusted for potential confounder factors.
majority of our RA patients were not on dialysis due to end
stage renal disease as the final stage of a chronic kidney
disease. Additionally, the population assessed in that study
was very heterogeneous, including both black and white
individuals.
Nevertheless, even though our results are negative, we
feel that these negative data are of potential interest and they
may be of help to establish future lines of research. Further
studies aimed at determining the potential influence of poly-
morphisms located in genes implicated in the inflammatory
pathways on the risk of CV disease in RA are warranted.
5. Conclusion
Our results do not confirm association between JAK3 poly-
morphisms and CV disease in RA.
Table 6: Association between cIMT values and JAK3 polymor-
phisms in RA patients stratified according to RF status.
Subgroup 𝐽𝐴𝐾3 Genotypes/alleles cIMT (mm) 𝑃∗
Mean ± SD
RF positive
rs3212780
GG (𝑛 = 192) 0.73 ± 0.16 0.41
GA (𝑛 = 132) 0.73 ± 0.17
AA (𝑛 = 26) 0.79 ± 0.25
G (𝑛 = 516) 0.73 ± 0.16 0.42
A (𝑛 = 184) 0.75 ± 0.19
rs3212752
TT (𝑛 = 312) 0.74 ± 0.17 0.52
TC (𝑛 = 38) 0.73 ± 0.17
CC (𝑛 = 0) —
T (𝑛 = 662) 0.73 ± 0.17 0.54
C (𝑛 = 38) 0.73 ± 0.17
Haplotypes
GT (𝑛 = 498) 0.73 ± 0.16 0.67
AT (𝑛 = 164) 0.75 ± 0.19
AC (𝑛 = 20) 0.72 ± 0.19
GC (𝑛 = 18) 0.74 ± 0.14
RF negative
rs3212780
GG (𝑛 = 116) 0.73 ± 0.16 0.95
GA (𝑛 = 93) 0.74 ± 0.17
AA (𝑛 = 20) 0.76 ± 0.15
G (𝑛 = 325) 0.73 ± 0.16 0.84
A (𝑛 = 133) 0.74 ± 0.16
rs3212752
TT (𝑛 = 203) 0.73 ± 0.17 0.20
TC (𝑛 = 24) 0.78 ± 0.16
CC (𝑛 = 0) —
T (𝑛 = 430) 0.73 ± 0.17 0.21
C (𝑛 = 24) 0.78 ± 0.16
Haplotypes
GT (𝑛 = 312) 0.73 ± 0.17 0.40
AT (𝑛 = 118) 0.74 ± 0.17
AC (𝑛 = 15) 0.76 ± 0.16
GC (𝑛 = 9) 0.81 ± 0.16
cIMT: carotid intima-media thickness; RA: rheumatoid arthritis; RF:
rheumatoid factor; SD: standard deviation.
∗Adjusted for potential confounder factors.
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